



## Robert H. Weiss, M.D.

<b>Clinical Interests</b>	Robert H. Weiss' clinical interests include the diagnosis and treatment of all renal diseases and electrolyte problems. His research interests concern the cyclins and cyclin inhibitors, cancer growth control (kidney and breast cancer), metabolomics and proteomics, and polycystic kidney disease.
<b>Title</b>	Chief of Nephrology, Sacramento VA Medical Center Professor
<b>Specialty</b>	Internal Medicine, Nephrology
<b>Department</b>	Internal Medicine
<b>Division</b>	Nephrology
<b>Center/Program Affiliation</b>	<a href="#">UC Davis Comprehensive Cancer Center</a>
<b>Address/Phone</b>	Lawrence J. Ellison Ambulatory Care Center, Nephrology Clinic, 4860 Y St. Suite 0200 Sacramento, CA 95817 <b>Phone:</b> 916-734-3761
<b>Additional Phone</b>	Phone: 800-4-UCDAVIS (800-482-3284)
<b>Education</b>	M.D., UC Irvine College of Medicine, Irvine, California, 1984 B.A., UC Santa Cruz, Santa Cruz, California, 1976 M.S., UCLA, Los Angeles, California, 1980
<b>Internships</b>	California-Pacific Medical Center, San Francisco, California, 1984-1985
<b>Residency</b>	California-Pacific Medical Center, San Francisco, California, 1985-1987
<b>Fellowships</b>	University of California, San Francisco, San Francisco, California, 1991
<b>Board Certifications</b>	American Board of Internal Medicine, 1987 American Board of Internal Medicine, Nephrology, 1996
<b>Professional Memberships</b>	American Association for the Advancement of Science American College of Physicians American Society of Nephrology
<b>Select Recent Publications</b>	Chen H, Li C, Huang j, Cung T, Seiss K, Beamon J, Carrington MF, Porter LC, Burke PS, Yang Y, Ryan BJ, Kiu R, Weiss RH, Preyra F, Cress WD, Brass AL, Rosenberg ES, Walker BD, Yu XG,



## Robert H. Weiss, M.D.

Lichterfeld M. CD4 T cells from elite controllers resist HIV-1 infection by selective upregulation of p21 cip-1/waf-1. *Journal of Clinical Investigation*. 2011 Apr 1;121(4):1549-60.

Kim K, Taylor SL, Ganti S, Guo L, Osier M, Weiss RH. Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer, *Omics*, 2011 May;15(5):293-303.

Taylor SL, Ganti S, Bukanov NO, Chapman A, Fiehn O, Osier M, Kim K, Weiss RH. A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease. *American Journal of Physiology: Renal Physiology*. 2010 298:909-922, with Editorial Forum

Weiss, RH. Invited editorial (Weiss: Editor-in-Chief): Why another cancer journal? *Cancers*, 1(1): 1-2, 2009

Perroud, B., Ishimaru, T., Borowsky, A.D., Weiss, RH. Grade-dependent proteomic characterization of kidney cancer, *Molecular and Cellular Proteomics*, May; 8(5):971-85, 2009

Kim, K.M., Aronov, P.A., Zakharkin, S.O., Anderson, D., Perroud, B., Weiss, RH., Urine metabolomic analysis for kidney cancer detection and biomarker discovery, *Molecular and Cellular Proteomics*, Mar; 8(3):558-70, 2009

Liu, J.-Y. Park, S.-H., Morisseau, C., Hwang, S. H., Hammock, B., Weiss, RH., Sorafenib Has the Inhibitory Activity Which Contributes to Its Effect Profile in vivo, *Molecular Cancer Therapeutics*, 2009 Aug; 8(8):2193-203, 2009

Park SH, Wang X, Liu R, Lam KS, Weiss RH. High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers, *Cancer Biology Therapy* 2008 Dec 26;7(12).

© 2015 UC Regents